White Shield

Interest-Based Ads

Advertising Cookies: We would like to set third-party advertising cookies on your browser for this health-related website to help us serve relevant health-related advertisements to you about our products or services when you visit other websites. For more information, visit our Privacy Policy. Do you want to set these advertising cookies on this browser?

Find A PLUVICTO Treatment Center
Patients HCP
This site is for US residents only.

Patient Support Line 1-844-638-7222, Monday-Friday, 8:00 AM – 8:00 PM ET, excluding holidays.

PLUVICTO. Every day without progression is a VICTORY. Now available before chemotherapy for PSMA+ mCRPC* *For certain men as determined by their doctor.

After hormone therapy, men with PSMA+ mCRPC who received PLUVICTO saw:

More time without their cancer progressing, with a median of 9.3 months vs 5.6 months with a second hormone therapy

Their tumors shrink or disappear, 49% of the time vs 14% with a second hormone therapy

How does targeted treatment work for PSMA+ mCRPC?

Explore PLUVICTO

PLUVICTO is given in up to 6 doses every 6 weeks

Discover what to expect

Brochures and pamphlets can support you or your loved one

Find helpful materials

Interested in receiving information about PLUVICTO?

PLUVICTO® Pulse provides educational support and materials for those considering and starting on treatment.

Sign Up Today

mCRPC, metastatic castration-resistant prostate cancer; PSMA+, prostate-specific membrane antigen positive.